Namodenoson

Can-Fite BioPharma has secured $3 million through a registered direct offering of 2.5 million American Depositary Shares priced at $1.20 per ADS, with the transaction expected to close by April 15, 2025.

Can-Fite BioPharma has initiated a pivotal Phase 3 clinical trial for Piclidenoson, an oral drug targeting moderate to severe plaque psoriasis, with protocols approved by both FDA and EMA regulatory authorities.

A patient with decompensated liver cirrhosis demonstrated significant clinical improvement after 20 months of Namodenoson treatment, including resolution of moderate ascites and no further variceal bleeding episodes.

The advanced liver cancer market is projected to grow from $2.31 billion in 2024 to $11.13 billion by 2035, exhibiting a CAGR of 15.38%, according to IMARC Group research.

Can-Fite BioPharma's Namodenoson demonstrates liver-protective effects alongside its anti-cancer activity in hepatocellular carcinoma (HCC).